ImmuCell Announces Correction to its Reported Unaudited Loss Per Share from ($0.06) to ($0.04) for the Quarter Ended December...
February 19 2020 - 12:35PM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically-proven and
practical products that improve the health and productivity of
dairy and beef cattle, today announced a correction to its
unaudited loss per share calculation for the fourth quarter ended
December 31, 2019.
The unaudited weighted average shares outstanding was
incorrectly reported as 5,408,000 resulting in a loss per share
calculation of ($0.06). The corrected unaudited weighted average
shares outstanding is 7,210,000 resulting in a loss per share
calculation of ($0.04).
- Net loss was ($310,000), or ($0.04) per share, during the
fourth quarter of 2019 in comparison to net loss of ($1,052,000),
or ($0.19) per share, during the fourth quarter of 2018.
Conference Call: Interested parties can access
a replay of the February 19, 2020 teleconference held by the
Company by dialing (877) 344-7529 (toll free) or (412) 317-0088
(international), utilizing confirmation #10138781 until February
26, 2020. Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business and is available under the “Investors” tab of
the Company’s website at www.immucell.com, or by request to the
Company. The Company expects to file its Annual Report on Form 10-K
on or about March 27, 2020.
About ImmuCell: ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create
scientifically-proven and practical products that improve the
health and productivity of dairy and beef cattle. ImmuCell
markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
livestock, and is in the late stages of developing
Re-Tain™, a novel treatment for subclinical
mastitis without a milk discard requirement that provides an
alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Contact:
Michael F. Brigham, President and CEOImmuCell Corporation(207)
878-2770
Joe Diaz, Robert Blum and Joe DorameLytham Partners, LLC(602)
889-9700iccc@lythampartners.com
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024